NS

Ning Shen

FT Fulcrum Therapeutics: 4 patents #3 of 17Top 20%
BC Beijing Hanmi Pharmaceutical Co.: 1 patents #11 of 41Top 30%
SC Shanghai Haihe Pharmaceutical Co.: 1 patents #16 of 51Top 35%
📍 Beijing, MA: #132 of 173 inventorsTop 80%
Overall (All Time): #815,297 of 4,157,543Top 20%
6
Patents All Time

Issued Patents All Time

Showing 1–6 of 6 patents

Patent #TitleCo-InventorsDate
11479770 Use of p38 inhibitors to reduce expression of DUX4 Angela Cacace, Luis Gustavo Alejandro Rojas Soto, Lorin A. Thompson, III, Owen Brendan Wallace, Lucienne V. Ronco +2 more 2022-10-25
11465984 Compound having ERK kinase inhibitory activity and use thereof Lei Li, Meiyu Geng, Ying-Huey Huang, Jian Ding, Qiong Zhang +3 more 2022-10-11
11291659 P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD Angela Cacace, Luis Gustavo Alejandro Rojas Soto, Lorin A. Thompson, III, Owen Brendan Wallace, Lucienne V. Ronco +2 more 2022-04-05
10537560 P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD Angela Cacace, Luis Gustavo Alejandro Rojas Soto, Lorin A. Thompson, III, Owen Brendan Wallace, Lucienne V. Ronco +2 more 2020-01-21
10342786 P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD Angela Cacace, Luis Gustavo Alejandro Rojas Soto, Lorin A. Thompson, III, Owen Brendan Wallace, Lucienne V. Ronco +2 more 2019-07-09
9453062 Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof Tao Ma, Shusen XU, Zhijun Liu, Bo Zhang, Hai Yang +4 more 2016-09-27